Skip to main content
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · IEX Real-Time Price · USD
6.92
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
7.00
+0.08 (1.16%)
Pre-market: Jul 20, 2024, 9:29 AM EDT

TScan Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
 TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Revenue
14.8121.0513.5410.141.090
Revenue Growth (YoY)
-14.47%55.52%33.47%834.65%--
Gross Profit
14.8121.0513.5410.141.090
Selling, General & Admin
25.6726.3520.3513.836.744.77
Research & Development
91.2388.1559.8244.9520.589.44
Operating Expenses
116.9114.5180.1758.7827.3214.21
Operating Income
-102.09-93.46-66.64-48.64-26.23-14.21
Interest Expense / Income
3.763.761.18000
Other Expense / Income
-9.05-8-1.59-0.02-0.11-0.55
Pretax Income
-96.8-89.22-66.22-48.63-26.13-13.66
Net Income
-96.8-89.22-66.22-48.63-26.13-13.66
Shares Outstanding (Basic)
9566241210
Shares Outstanding (Diluted)
9566241210
Shares Change
291.63%172.78%106.20%1173.20%137.87%-
EPS (Basic)
-1.18-1.36-2.75-4.17-28.52-35.47
EPS (Diluted)
-1.18-1.36-2.75-4.17-28.52-35.47
Free Cash Flow
-70.05-64.5-70.73-58.62-7.26-13.77
Free Cash Flow Per Share
-0.74-0.98-2.94-5.03-7.93-35.76
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-689.22%-444.00%-492.32%-479.65%-2417.79%-
Profit Margin
-653.50%-423.86%-489.26%-479.49%-2408.02%-
Free Cash Flow Margin
-472.93%-306.45%-522.56%-578.03%-669.22%-
EBITDA
-87.92-80.1-59.91-45.3-24.9-13.14
EBITDA Margin
-593.57%-380.53%-442.62%-446.67%-2294.65%-
Depreciation & Amortization
5.125.365.143.331.230.52
EBIT
-93.04-85.46-65.05-48.63-26.13-13.66
EBIT Margin
-628.11%-406.00%-480.57%-479.49%-2408.02%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).